Dabigatran Etexilate: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Dabigatran Etexilate. Educational only — not medical advice.
Labeled uses
PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Source: FDA labeling via NIH DailyMed (set 5db7f199…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.